Kennedy Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Kennedy Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-133,117	Closed	-$323K	–	540
2025 Q4	$323K	Buy	133,117 +3,173	+2%	+$11.2K	0.01%	517
2025 Q3	$492K	Buy	129,944 +64,069	+97%	+$187K	0.01%	533
2025 Q2	$163K	Buy	65,875 +2,352	+4%	+$4.53K	﹤0.01%	573
2025 Q1	$98.5K	Sell	63,523 -370,270	-85%	-$776K	﹤0.01%	637
2024 Q4	$928K	Sell	433,793 -223,243	-34%	-$640K	0.02%	601
2024 Q3	$2.86M	Sell	657,036 -46,247	-7%	-$252K	0.06%	437
2024 Q2	$3.28M	Sell	703,283 -13,900	-2%	-$74.6K	0.07%	427
2024 Q1	$3.64M	Sell	717,183 -23,718	-3%	-$95.6K	0.07%	396
2023 Q4	$2.08M	Sell	740,901 -9,391	-1%	-$22K	0.05%	485
2023 Q3	$2.15M	Sell	750,292 -1,111	-0.1%	-$4.09K	0.05%	446
2023 Q2	$3.79M	Buy	+751,403	New	+$1.53M	0.09%	351

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Kennedy Capital Management's BDTX Position: Q1 2026 in Review

Kennedy Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 133,117 shares — an estimated $323K sold.

Kennedy Capital Management first reported a position in BDTX in Q2 2023 and held it in 11 quarters. The position peaked at $3.79M in Q2 2023. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Kennedy Capital Management reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
Kennedy Capital Management sold 133,117 Black Diamond Therapeutics shares in Q1 2026, an estimated $323K.
Kennedy Capital Management first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 11 quarters.
Kennedy Capital Management's Black Diamond Therapeutics position peaked at $3.79M in Q2 2023.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.